Liu Jingzhen, chairman of China National Pharmaceutical Group (Sinopharm), attends a news conference on vaccines for the coronavirus disease (COVID-19), in Beijing, China October 20, 2020. REUTERS/Carlos Garcia Rawlins
BEIJING (Reuters) - China National Pharmaceutical Group (Sinopharm), one of several Chinese firms developing coronavirus vaccines, said it may have the capacity to produce more than 1 billion doses in 2021, Chairman Liu Jingzhen said on Tuesday.
About 60,000 people have received Chinese coronavirus vaccine candidates during Phase III clinical trials, with no serious side effects reported so far, Tian Baoguo, an official at China's Ministry of Science and Technology, said at the same government media briefing.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
